Results 211 to 220 of about 137,029 (384)

Canadian Association of Gastroenterology Clinical Practice Guidelines: The Use of Infliximab in Crohn's Disease [PDF]

, 2001
Richard N. Fedorak
openalex   +1 more source

Outcomes of Fecal Diversion in Perianal Crohn's Disease: A Systematic Review and Meta‐Analysis

Journal of Digestive Diseases, EarlyView.
Fecal diversion provides symptom control in patients with perianal fistulising Crohn’s disease, with a 65% clinical improvement rate. However, bowel restoration is achieved in only 29% of cases, and many require re‐diversion or proctectomy/protocolectomy.
Imogen Hartley, Babak Sarraf, Helen Wilding, Jonathan P. Segal, Nik Sheng Ding   +4 more
wiley   +1 more source

Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease [PDF]

, 2001
Freddy Cornillie, David J. Shealy, Geert D’Haens, Karel Geboes, Gert Van Assche, Jan Ceuppens, Carrie Wagner, T Schaible, Scott E. Plevy, Stephan R. Targan, P. Rutgeerts   +10 more
openalex   +1 more source

Health Equity and Secukinumab for Severe Psoriasis in New Zealand

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Background/Objectives The only funded indication in New Zealand between October 2018 and April 2021 for the biologic secukinumab, an interleukin‐17A antibody, was severe psoriasis. This unique period of limited availability of secukinumab allowed the evaluation of who received it and health equity.
Anna Luo, Amanda Oakley, Dug Yeo Han, Paul Jarrett   +3 more
wiley   +1 more source

Relative increase of IL-10 producing peripheral blood T lymphocytes after anti-TNF-A chimeric antibody (infliximab) treatment in fistulizing Crohn's disease

, 2000
Nancy Van Damme, Filip De Keyser, Dominique Baeten, Pieter Demetter, Dirk Elewaut, Claude Cuvelier, Herman Mielants, Gust Verbruggen, Eric Veys, Martine De Vos   +9 more
openalex   +1 more source

Management Strategies for Generalised Granuloma Annulare: A Systematic Review of Current and Emerging Therapies

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Generalised Granuloma Annulare (GGA) is a chronic inflammatory skin disorder with no standard treatment. Since the last review in 2013, new treatments and varied responses have highlighted the need for an updated synthesis to guide clinical decisions.
Luca Bettolini, Vincenzo Maione, Andrea Carugno, Giorgio Stabile, Antonio Podo Brunetti, Zeno Fratton, Enzo Errichetti, Nicola Zerbinati, Franco Rongioletti, Piergiacomo Calzavara‐Pinton, Mariateresa Rossi, Stefano Bighetti   +11 more
wiley   +1 more source

Infliximab blinds human monocytes but not mucosal T cells in vitro: No direct anti-T-cell mechanism of action

, 2000
Subra Kugathasan, Angie R. Taras, Dan J. Stein, Pamela J. Fisher, Thomas H. Lamirand, Mong-Shang Lin, T Schaible, Carrie Wagner, Robert L. Truitt, David G. Binion   +9 more
openalex   +1 more source

Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system

Andrology, EarlyView.
Abstract Background Growing evidence indicates that paternal condition significantly influences pregnancy outcomes and offspring health. However, assessing the safety of paternal drug exposure via randomized controlled trials poses ethical challenges, and relevant clinical studies consume a lot of resources to evaluate only a few drugs.
Yanbin Zeng, Wanlong Lin, Wei Zhuang
wiley   +1 more source

OP0059 Infliximab in refractory spondyloarthropathies; preliminary results in a spanish population [PDF]

, 2001
Eduardo Collantes‐Estévez, MC Muñoz-Villanueva, Raimón Sanmartí, JD Cañete, Jordi Gratacós, Pedro Zarco, Carlos González, JC Torre   +7 more
openalex   +1 more source

Infliximab for ulcerative colitis

Digestive and Liver Disease, 2002
Simmons, J, Jewell, D
openaire   +3 more sources